Literature DB >> 20861910

IDH mutations and trisomy 8 in myelodysplastic syndromes and acute myeloid leukemia.

D Caramazza, T L Lasho, C M Finke, N Gangat, D Dingli, R A Knudson, S Siragusa, C A Hanson, A Pardanani, R P Ketterling, A Tefferi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20861910     DOI： 10.1038/leu.2010.213

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   12.883


× No keyword cloud information.
  12 in total

1.  Prognostic gene mutations and distinct gene- and microRNA-expression signatures in acute myeloid leukemia with a sole trisomy 8.

Authors:  Guido Marcucci; Clara D Bloomfield; Heiko Becker; Kati Maharry; Krzysztof Mrózek; Stefano Volinia; Ann-Kathrin Eisfeld; Michael D Radmacher; Jessica Kohlschmidt; Klaus H Metzeler; Sebastian Schwind; Susan P Whitman; Jason H Mendler; Yue-Zhong Wu; Deedra Nicolet; Peter Paschka; Bayard L Powell; Thomas H Carter; Meir Wetzler; Jonathan E Kolitz; Andrew J Carroll; Maria R Baer; Michael A Caligiuri; Richard M Stone
Journal:  Leukemia       Date:  2014-03-21       Impact factor: 11.528

Review 2.  Mutations in epigenetic regulators in myelodysplastic syndromes.

Authors:  Gorica Nikoloski; Bert A van der Reijden; Joop H Jansen
Journal:  Int J Hematol       Date:  2012-01-11       Impact factor: 2.490

Review 3.  Metabolic interactions with cancer epigenetics.

Authors:  Xia Gao; Michael A Reid; Mei Kong; Jason W Locasale
Journal:  Mol Aspects Med       Date:  2016-09-09

4.  Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.

Authors:  Amir T Fathi; Omar Abdel-Wahab
Journal:  Adv Hematol       Date:  2011-06-26

5.  Rare mutations in DNMT3A in myeloproliferative neoplasms and myelodysplastic syndromes.

Authors:  M Brecqueville; N Cervera; V Gelsi-Boyer; A Murati; J Adélaïde; M Chaffanet; J Rey; N Vey; M J Mozziconacci; D Birnbaum
Journal:  Blood Cancer J       Date:  2011-05-13       Impact factor: 11.037

6.  IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F.

Authors:  A Tefferi; T Jimma; N H Sulai; T L Lasho; C M Finke; R A Knudson; R F McClure; A Pardanani
Journal:  Leukemia       Date:  2011-09-13       Impact factor: 11.528

Review 7.  Isocitrate dehydrogenase mutations in leukemia.

Authors:  Anna Sophia McKenney; Ross L Levine
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 19.456

8.  Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: a retrospective cohort study and meta-analysis.

Authors:  Jie Jin; Chao Hu; Mengxia Yu; Feifei Chen; Li Ye; Xiufeng Yin; Zhengping Zhuang; Hongyan Tong
Journal:  PLoS One       Date:  2014-06-17       Impact factor: 3.752

9.  Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium.

Authors:  A Tefferi; O Abdel-Wahab; F Cervantes; J D Crispino; G Finazzi; F Girodon; H Gisslinger; J Gotlib; J-J Kiladjian; R L Levine; J D Licht; A Mullally; O Odenike; A Pardanani; R T Silver; E Solary; T Mughal
Journal:  Blood Cancer J       Date:  2011-03-04       Impact factor: 11.037

Review 10.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies.

Authors:  A P Im; A R Sehgal; M P Carroll; B D Smith; A Tefferi; D E Johnson; M Boyiadzis
Journal:  Leukemia       Date:  2014-04-04       Impact factor: 12.883
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.